SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (12373)12/2/1999 10:29:00 PM
From: Bluegreen  Read Replies (2) | Respond to of 17367
 
George, in my opinion our anti Psoriasis drug will be the gold standard on which Biogen's and others will be compared against. Thank goodness Xoma never did what IPIC did today.......in my opinion IPIC gave away their product for peanuts.



To: aknahow who wrote (12373)12/4/1999 9:58:00 PM
From: franksja  Read Replies (1) | Respond to of 17367
 
Received this article from XOMA IR. It's 1998, Vol. 10, page 45-49 of Current Opinion in Immunology 1998, 10:45-49. You may have to register, but it's free. Good article. Describes BPI as an antibiotic.

biomednet.com


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News